|Dr. Martine A. Rothblatt Ph.D., J.D., M.B.A.||Founder, Chairman & CEO||2.23M||16.5M||62|
|Mr. Michael I. Benkowitz||Pres & COO||1.27M||N/A||45|
|Mr. James C. Edgemond||CFO & Treasurer||972.46k||N/A||49|
|Mr. Paul A. Mahon J.D.||Exec. VP, Gen. Counsel & Corp. Sec.||1.38M||N/A||53|
|Dr. Roger A. Jeffs Ph.D.||Sr. Advisor||6.52M||N/A||55|
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The companys product candidates include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, a once-daily PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also provides Unituxin for the treatment of pediatric patients with high-risk neuroblastoma who achieve a partial response to prior first-line multiagent multimodality therapy. In addition, the company develops RemoSynch and RemUnity delivery systems for intravenous and subcutaneous Remodulin; esuberaprost and eNOS gene therapies for PAH; and organ transplantation-related technologies, including regenerative medicines, xenotransplantation, and ex-vivo lung perfusion. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.
United Therapeutics Corporation’s ISS Governance QualityScore as of September 1, 2017 is 4. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 9; Compensation: 1.